[go: up one dir, main page]

PE20091310A1 - Nueva forma cristalina b del acido (2r)-(3-amino-2-fluoropropil)fosfinico - Google Patents

Nueva forma cristalina b del acido (2r)-(3-amino-2-fluoropropil)fosfinico

Info

Publication number
PE20091310A1
PE20091310A1 PE2008002133A PE2008002133A PE20091310A1 PE 20091310 A1 PE20091310 A1 PE 20091310A1 PE 2008002133 A PE2008002133 A PE 2008002133A PE 2008002133 A PE2008002133 A PE 2008002133A PE 20091310 A1 PE20091310 A1 PE 20091310A1
Authority
PE
Peru
Prior art keywords
fluoropropyl
amino
crystalline
phosphinic acid
new crystalline
Prior art date
Application number
PE2008002133A
Other languages
English (en)
Inventor
Ida Hoyer
Thomas Larsson
Jeroen Koningen
Erica Tjerneld
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40801457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091310(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091310A1 publication Critical patent/PE20091310A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA FORMA CRISTALINA B DEL ACIDO (2R)-(3-AMINO-2-FLUOROPROPIL)FOSFINICO QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X EN POLVOS QUE PRESENTA PICOS CON VALORES d: 6,2 Å, 4,10 Å, 4,05 Å, 2,87 Å, 2,60 Å Y 2,47 Å. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION DE DICHA FORMA CRISTALINA B QUE CONSISTE EN DISOLVER LA FORMA CRISTALINA A DEL ACIDO (2R)-(3-AMINO-2-FLUOROPROPIL)FOSFINICO EN UN SOLVENTE POLAR TAL COMO METANOL O AGUA, AGREGAR UN ANTI-SOLVENTE TAL COMO ACETONITRILO, ACETONA, ETANOL, ISOPROPANOL, ACETATO DE ETILO O UNA MEZCLA DE ELOS Y AGITAR A UNA TEMPERATURA DE 40 ºC DURANTE UN PERIODO DE 33 HORAS. LA FORMA CRISTALINA B ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS GASTROINTESTINALES
PE2008002133A 2007-12-21 2008-12-18 Nueva forma cristalina b del acido (2r)-(3-amino-2-fluoropropil)fosfinico PE20091310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1576607P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
PE20091310A1 true PE20091310A1 (es) 2009-09-30

Family

ID=40801457

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002133A PE20091310A1 (es) 2007-12-21 2008-12-18 Nueva forma cristalina b del acido (2r)-(3-amino-2-fluoropropil)fosfinico

Country Status (8)

Country Link
US (1) US20110034420A1 (es)
EP (1) EP2235027A4 (es)
AR (1) AR070045A1 (es)
CL (1) CL2008003841A1 (es)
PE (1) PE20091310A1 (es)
TW (1) TW200940559A (es)
UY (1) UY31558A1 (es)
WO (1) WO2009082345A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2235026A4 (en) * 2007-12-21 2011-08-17 Astrazeneca Ab NEW PROCESS FOR THE PREPARATION OF (2R) - (3-AMINO-2-FLUORO-PROPYL) PHOSPHIC ACID FORM A

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
FR2810824B1 (fr) * 2000-06-26 2003-01-17 Cit Alcatel Dispositif de fixation pour appareil de telecommunication mobile
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
WO2009014490A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Combination of (3-amino-2-fluoropropyl)phosphinic acid and omeprazole for treating tlesr, gerd, and nerd
US20100317626A1 (en) * 2007-07-25 2010-12-16 Astrazeneca Ab The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy

Also Published As

Publication number Publication date
US20110034420A1 (en) 2011-02-10
CL2008003841A1 (es) 2010-04-16
EP2235027A4 (en) 2011-06-22
WO2009082345A1 (en) 2009-07-02
AR070045A1 (es) 2010-03-10
EP2235027A1 (en) 2010-10-06
TW200940559A (en) 2009-10-01
UY31558A1 (es) 2009-08-03

Similar Documents

Publication Publication Date Title
ES2674174T3 (es) Antagonista de LPA1 policíclico y usos del mismo
AR076974A1 (es) Metodo para sintetizar pirfenidona
JP2011518833A5 (es)
UA105229C2 (uk) Фармацевтичний склад
ME02558B (me) Inhibitori replikacije virusa gripa
CO6612214A2 (es) Método para producir un biocida de oxidación estable
CO6400226A2 (es) Micrólido anti-inflamatorio
WO2013086540A3 (en) Patient transporter with expandable/deployable support structure
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
WO2010136814A3 (en) Electrodeposition of elemental zirconium
PE20091310A1 (es) Nueva forma cristalina b del acido (2r)-(3-amino-2-fluoropropil)fosfinico
PE20091165A1 (es) Hidratos de difenilazetidinona cristalinos y composiciones que comprenden a estos compuestos
PE20090192A1 (es) Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo
HRP20220031T1 (hr) Kristalni trihidratni oblik (3s,3s') 4,4'-disulfanedilbis (3-aminobutan 1-sulfonske kiseline)
PE20131327A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen
IL206032A0 (en) Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
AR068978A1 (es) N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas
RU2009137110A (ru) Способ получения фрактальных кластеров на основе l-цистеина
WO2011091335A3 (en) Ammonia salt fuel system
MX2010008707A (es) Composiciones farmaceuticas de entacapona comicronizada con alcoholes de azucar.
CL2012001528A1 (es) Proceso para preparar la forma cristalina a de ilaprazol a partir de una sal inorganica de ilaprazol y posterior neutralizacion de la sal con un acido en un solvente de reaccion; y proceso para preparar la forma cristalina b de ilaprazol en la forma cristalina a de ilaprazol.
ES1068172Y (es) "condensador para obtener agua del ambiente"
PE20121353A1 (es) Procedimiento de preparacion del acido 4-nitro-oxi-metil-benzoico
Lee et al. Synthesis and in vitro evaluation of 99m Tc-diglucosediethylenetriamine (DGTA) as a potential tumor imaging agent
潘雯 Creatures of the Night

Legal Events

Date Code Title Description
FD Application declared void or lapsed